ALZFORUM | NETWORKING FOR A CURE
3 days ago · Most scientists agree that for amyloidosis to ignite, both ApoE and microglia need to be present. A new study presents a mechanistic link between the two. Scientists report that ApoE and Aβ both aggregate within microglial lysosomes, and that these intracellular liaisons ultimately seed amyloid plaques.
Leqembi - ALZFORUM
Overview. Name: Leqembi Synonyms: Lecanemab-irmb, BAN2401, mAb158 Therapy Type: Immunotherapy (passive) Target Type: Amyloid-Related Condition(s): Alzheimer's Disease U.S. FDA Status: Alzheimer's Disease (Approved) Company: BioArctic AB, Biogen, Eisai Co., Ltd. Background. BAN2401 is the humanized IgG1 version of the mouse monoclonal antibody mAb158, which selectively binds to large, soluble ...
Paper Alert: p-Tau217 Blood Test Predicts Plaques, Tangles
Jan 24, 2024 · Plasma p-tau 217 measured with this assay distinguished amyloid-positive participants from those without plaques with areas under the curve of 0.92 to 0.96 across the three cohorts. AUC measures specificity and sensitivity, with 1 being perfect. The assay was similarly accurate in detecting tau pathology, with AUCs of 0.93 to 0.97.
Memantine - ALZFORUM
Memantine's side effects include fatigue, increases in blood pressure, dizziness, headache, constipation, confusion, and sleepiness, among others. Memantine is the only FDA-approved drug for the treatment of Alzheimer's disease that is not an acetyl cholinesterase inhibitor. The drug is a noncompetitive, low- to medium-affinity antagonist of ...
Donanemab | ALZFORUM
Feb 14, 2019 · Overview. Name: Donanemab Synonyms: N3pG-Aβ Monoclonal Antibody, LY3002813, Kisunla Therapy Type: Immunotherapy (passive) Target Type: Amyloid-Related Condition(s): Alzheimer's Disease U.S. FDA Status: Alzheimer's Disease (Approved) Company: Eli Lilly & Co. Background. Donanemab, aka N3pG, is a humanized IgG1 monoclonal antibody developed from mouse mE8-IgG2a. This biologic drug recognizes ...
Latozinemab - ALZFORUM
Jul 10, 2024 · AL001 is a recombinant human anti-human sortilin (SORT1) monoclonal IgG1 developed by Alector in partnership with Abbvie. In June 2018, this antibody received orphan drug designation from the U.S. FDA for the treatment of frontotemporal dementia. Sortilin is a type I membrane glycoprotein in the vacuolar protein sorting 10 protein (Vps10p) family.
Donepezil - ALZFORUM
Donepezil's most common side effects are gastrointestinal, i.e., diarrhea, nausea, and vomiting; dizziness, sleeplessness/fatigue, and urinary incontinence also have been reported. These are known class effects of cholinergic therapies, and often occur primarily at the beginning of treatment. One post-hoc analysis reported an inverse ...
Relyvrio - ALZFORUM
Overview. Name: Relyvrio Synonyms: Albrioza, AMX0035 Therapy Type: Combination, Small Molecule Target Type: Other Condition(s): Amyotrophic Lateral Sclerosis, Alzheimer's Disease U.S. FDA Status: Amyotrophic Lateral Sclerosis (Approved), Alzheimer's Disease (Phase 2) Company: Amylyx Pharmaceuticals Inc Approved for: ALS Background. AMX0035 is a proprietary, oral combination of two drugs ...
Bepranemab - ALZFORUM
Jan 23, 2022 · Overview. Name: Bepranemab Synonyms: UCB0107 , UCB 0107 , Antibody D Therapy Type: Immunotherapy (passive) Target Type: Tau Condition(s): Progressive Supranuclear Palsy, Alzheimer's Disease U.S. FDA Status: Progressive Supranuclear Palsy (Phase 1), Alzheimer's Disease (Phase 2) Company: Hoffmann-La Roche, UCB S.A. Background. This humanized, monoclonal IgG4 antibody binds to the central region ...
Trontinemab - ALZFORUM
May 9, 2024 · Overview. Name: Trontinemab Synonyms: RO7126209, RG6102 , Brain shuttle gantenerumab Therapy Type: Immunotherapy (passive) Target Type: Amyloid-Related Condition(s): Alzheimer's Disease U.S. FDA Status: Alzheimer's Disease (Phase 1/2) Company: Hoffmann-La Roche Background. RO7126209 is a new version of the anti-amyloid monoclonal antibody gantenerumab, engineered to more easily cross the blood ...